The role of interferons in the treatment of multiple sclerosis.
IFN beta-1b clearly alters the course of disease in patients with relapsing-remitting MS, although the adverse effects of this agent may discourage some patients from continuing the therapy. Nurses can help patients with MS minimize adverse effects through teaching. A double-blind, placebo-controlled clinical trial in patients with relapsing-progressive MS will be started in 1995. It is hoped that IFN beta-1b will be effective in slowing the accumulation of CNS lesions in those with progressive MS.